Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A 2-dose regimen of the vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN) can generate neutralizing antibodies for monkeypox virus clades Ib and IIb. We observed higher response to clade IIb; that result provides evidence that MVA-BN vaccination can induce cross-neutralizing antibodies for monkeypox virus clade Ib as well as for clade IIb.

More information Original publication

DOI

10.3201/eid3202.251553

Type

Journal article

Publication Date

2026-02-01T00:00:00+00:00

Volume

32

Pages

302 - 305

Total pages

3

Keywords

MVA-BN vaccination, United Kingdom, monkeypox virus, mpox, neutralization, viruses, zoonoses, Humans, Antibodies, Viral, Monkeypox virus, Antibodies, Neutralizing, United Kingdom, Mpox, Monkeypox, Vaccination, Smallpox Vaccine, Adult, Female, Male, Vaccinia virus, Young Adult, Healthy Volunteers, Middle Aged